SCHEMBL6761973

SCHEMBL6761973

O=C(O)c1cc(NCc2ccccc2)ccn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.57
ASPH Q12797 3/20 0.57
KDM8 Q8N371 3/20 0.57
RIOX2 Q8IUF8 1/20 0.57
HAO1 Q9UJM8 1/20 0.50
P4HTM Q9NXG6 1/20 0.48
HCAR2 Q8TDS4 1/20 0.47
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
KDM6B O15054 2/20 0.46
KDM4A O75164 2/20 0.46
KDM4D Q6B0I6 2/20 0.46
KDM4C Q9H3R0 2/20 0.46
KDM5B Q9UGL1 2/20 0.46
TET3 O43151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14875866 0.87 HDAC6 (0.54) MMP13
SCHEMBL18135105 0.85 KDR (0.48) KDM4EASPHKDM8HAO1NOS2
SCHEMBL14881168 0.85 KDM4E (0.59) KDM4EASPHKDM8RIOX2GRIN2B
SCHEMBL14875791 0.79 LMNA (0.44) MMP13
SCHEMBL7940761 0.79 KDM4E (0.52) KDM4EASPHKDM8GRIN2DGRIN3B
SCHEMBL23337477 0.77 ACVRL1 (0.55) KDM4EASPHKDM8P4HTMKDM6B
SCHEMBL28823850 0.77 HPGD (0.53) KDM4EP4HTMALDH1A1MMP13
SCHEMBL11398234 0.76 P4HTM (0.78) KDM4EASPHKDM8RIOX2HAO1
SCHEMBL10920047 0.76 F2 (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL27893661 0.76 GRIN2D (0.49) KDM4EGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103958475-B Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases F. HOFFMANN-LA ROCHE AG (CH) 2015-11-25 CN disclosed
EP-2776396-A2 HETEROARYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE F.HOFFMANN-LA ROCHE AG (CH) 2014-09-17 EP disclosed
CN-103958475-A Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases HOFFMANN LA ROCHE 2014-07-30 CN disclosed
CN-103958521-A Pyrimidin-4-one derivatives and their use in the treatment, alleviation or prevention of viral diseases HOFFMANN LA ROCHE 2014-07-30 CN disclosed
WO-2013057251-A2 HETEROARYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-04-25 WO disclosed
CN-1296346-C Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical SANOFI AVENTIS DEUTSCHLAND (DE) 2007-01-24 CN disclosed
US-6759412-B2 FOR PRODUCING DRUGS USED FOR THERAPY OF CARDIOVASCULAR DISEASES, STABLE OR UNSTABLE ANGINA PECTORIS, CORONARY HEART DISEASE, PRINZMETAL ANGINA, ACUTE CORONARY SYNDROME, HEART FAILURE, MYOCARDIAL INFARCTION, STROKE, THROMBOSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-07-06 US disclosed
CN-1491208-A Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical ������ҽҩ�¹����޹�˾ 2004-04-21 CN disclosed